Pfizer gaining antisense oligonucleotide in Excaliard buy
This article was originally published in Scrip
Executive Summary
In gobbling up tiny privately held biotech Excaliard Pharmaceuticals, New York-based Pfizer is gaining access to EXC 001, a Phase II antisense oligonucleotide designed to interrupt the process of fibrosis by inhibiting expression of connective tissue growth factor, which can be over expressed in damaged skin or tissue following surgery or traumatic injury and lead to disfiguring skin scarring.